# Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry

**Authors:** Anirban Kundu, Sulagna Giri, Atoshi Basu

PMC · DOI: 10.7759/cureus.103749 · 2026-02-16

## TL;DR

This paper describes a case where flow cytometry helped diagnose blastoid mantle cell lymphoma, avoiding confusion with acute leukemia.

## Contribution

The paper highlights the diagnostic utility of flow cytometry in resolving morphological challenges in blastoid mantle cell lymphoma.

## Key findings

- Flow cytometry distinguished blastoid MCL from ALL based on specific immunophenotypic markers.
- The case showed bright CD45 and positivity for CD19, CD20, CD5, and FMC7, but negativity for CD34, CD23, CD200, and CD10.
- Accurate diagnosis via flow cytometry ensured appropriate treatment and avoided misdiagnosis as acute leukemia.

## Abstract

Leukemic conversion of nodal mantle cell lymphoma (MCL) is most often detected as incidental lymphocytosis on routine blood counts, often mimicking chronic lymphocytic leukemia, with flow cytometric immunophenotyping being the gold-standard test for diagnosis. Blastoid MCL closely mimics acute lymphoblastic leukemia (ALL), thus posing significant diagnostic challenges. Blastoid transformation of MCL is usually associated with TP53 mutations, homozygous deletions of CDKN2A and CDKN2C, amplifications and overexpression of CDK4, and occasionally microdeletions of RB1, and is associated with an aggressive disease course. Equivocal cases require histopathological evaluation, fluorescent in-situ hybridization, or molecular studies for confirmation. We report the case of an 82-year-old female who presented with lower respiratory tract infection and was found to have severe anemia (hemoglobin: 45 g/L) and marked leukocytosis (325 × 10⁹/L) with 63% blastoid-appearing cells on peripheral blood smear, initially suggestive of acute leukemia. Flow cytometric immunophenotyping demonstrated bright CD45 expression with low side scatter and positivity for CD19, CD20, CD38, CD5, CD79b, and FMC7 with negativity for CD34, CD23, CD200, and CD10, suggesting blastoid transformation of MCL rather than de novo ALL. This case highlights the critical role of flow cytometry in distinguishing blastoid MCL from acute leukemia, thereby preventing misdiagnosis and ensuring appropriate therapeutic decision-making.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], CDKN2C (cyclin dependent kinase inhibitor 2C) [NCBI Gene 1031], CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019], RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925]
- **Proteins:** PTPRC (protein tyrosine phosphatase receptor type C), CD19 (CD19 molecule), MS4A1 (membrane spanning 4-domains A1), CD38 (CD38 molecule), CD5 (CD5 molecule), CD79B (CD79b molecule), MS4A1 (membrane spanning 4-domains A1), CD34 (CD34 molecule), FCER2 (Fc epsilon receptor II), CD200 (CD200 molecule), MME (membrane metalloendopeptidase)
- **Diseases:** mantle cell lymphoma (MONDO:0018876), chronic lymphocytic leukemia (MONDO:0004948), acute lymphoblastic leukemia (MONDO:0004967)

## Full-text entities

- **Genes:** CD200 (CD200 molecule) [NCBI Gene 4345] {aka MOX1, MOX2, MRC, OX-2}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CD34 (CD34 molecule) [NCBI Gene 947], CD79B (CD79b molecule) [NCBI Gene 974] {aka AGM6, B29, IGB, Igbeta}, FCER2 (Fc epsilon receptor II) [NCBI Gene 2208] {aka BLAST-2, CD23, CD23A, CLEC4J, FCE2, FCErII}, CDK4 (cyclin dependent kinase 4) [NCBI Gene 1019] {aka CMM3, MCPH31, PSK-J3}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, CDKN2C (cyclin dependent kinase inhibitor 2C) [NCBI Gene 1031] {aka INK4C, p18, p18-INK4C}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}
- **Diseases:** anemia (MESH:D000740), ALL (MESH:D054198), lymphocytosis (MESH:D008218), nodal (MESH:D013611), leukocytosis (MESH:D007964), respiratory tract infection (MESH:D012141), chronic lymphocytic leukemia (MESH:D015451), Blastoid MCL (MESH:D020522), acute leukemia (MESH:D015470)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13000355/full.md

---
Source: https://tomesphere.com/paper/PMC13000355